182 related articles for article (PubMed ID: 37448611)
1. Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.
Massanova M; Vere R; Robertson S; Crocetto F; Barone B; Dutto L; Ahmad I; Underwood M; Salmond J; Patel A; Celentano G; Bhatt JR
Curr Urol; 2023 Sep; 17(3):147-152. PubMed ID: 37448611
[TBL] [Abstract][Full Text] [Related]
2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
3. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
4. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
5. Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients.
Ryoo H; Kang MY; Sung HH; Chang Jeong B; Seo SI; Jeon SS; Lee HM; Jeon HG
Prostate Int; 2020 Sep; 8(3):125-129. PubMed ID: 33102394
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
8. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
9. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
10. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
11. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
12. Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies.
Wang C; Yuan L; Shen D; Zhang B; Wu B; Zhang P; Xiao J; Tao T
Front Oncol; 2022; 12():1024204. PubMed ID: 36465344
[TBL] [Abstract][Full Text] [Related]
13. Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study.
Lei Y; Li TJ; Gu P; Yang YK; Zhao L; Gao C; Hu J; Liu XD
Front Oncol; 2022; 12():992032. PubMed ID: 36212411
[TBL] [Abstract][Full Text] [Related]
14. PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone.
Wen J; Tang T; Ji Y; Zhang Y
Front Oncol; 2022; 12():861928. PubMed ID: 35463349
[TBL] [Abstract][Full Text] [Related]
15. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
Wang L; Luo Y; Liu T; Deng M; Huang X
Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
[TBL] [Abstract][Full Text] [Related]
16. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
[TBL] [Abstract][Full Text] [Related]
17. Cutoff Values of Prostate Imaging Reporting and Data System Version 2.1 Score in Men With Prostate-specific Antigen Level 4 to 10 ng/mL: Importance of Lesion Location.
Chen Y; Ruan M; Zhou B; Hu X; Wang H; Liu H; Liu J; Song G
Clin Genitourin Cancer; 2021 Aug; 19(4):288-295. PubMed ID: 33632569
[TBL] [Abstract][Full Text] [Related]
18. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
19. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
[TBL] [Abstract][Full Text] [Related]
20. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
